Atomoxetine

also known as Strattera · ATX · atomoxetine hydrochloride · ATMX · ATM · Atomoxetine HCl · ato · Atomoxetine only · +2 more

Other / unclassified

Developed for: attention deficit-hyperactivity disorder · obstructive sleep apnea syndrome · schizophrenia · cannabis dependence · dyslexia · oppositional defiant disorder · orthostatic hypotension · Parkinson disease
+39 more
· substance abuse · substance-related disorder · alcohol dependence · autism · cocaine dependence · cognitive disorder · Down syndrome · insomnia · reading disorder · social phobia · alcohol abuse · Alzheimer disease · autonomic nervous system disorder · binge eating disorder · cardiac rhythm disease · cognitive impairment with or without cerebellar ataxia · depressive disorder · fetal alcohol syndrome · Huntington disease · hypertensive disorder · methamphetamine dependence · multiple sclerosis · nicotine dependence · nocturnal enuresis · obesity-hypoventilation syndrome · opiate dependence · post-traumatic stress disorder · primary progressive freezing gait · schizoaffective disorder · spinal cord injury · Tourette syndrome · traumatic brain injury · type 1 diabetes mellitus · alcohol sensitivity, acute · alcohol-induced mental disorder · amnestic disorder · obesity due to melanocortin 4 receptor deficiency · substance dependence · syncope, familial vasovagal
Investigated by: Eli Lilly and Company · National Institute on Drug Abuse (NIDA) · Apnimed · Massachusetts General Hospital · Yale University · National Institute of Mental Health (NIMH)
+76 more
· University of Arizona · Brigham and Women's Hospital · Medical University of South Carolina · National Heart, Lung, and Blood Institute (NHLBI) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Icahn School of Medicine at Mount Sinai · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · New York State Psychiatric Institute · Rhode Island Hospital · Shire · Stanley Medical Research Institute · University of Maryland, Baltimore · University of Pittsburgh · VA Office of Research and Development · American Academy of Child Adolescent Psychiatry. · Boehringer Ingelheim · Bronx VA Medical Center · Brown University · Centre Hospitalier St Anne · Children's Hospital Medical Center, Cincinnati · China Medical University Hospital · Craig Hospital · Denver Health and Hospital Authority · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Göteborg University · Istituto Auxologico Italiano · Johns Hopkins University · Kyung Hee University Hospital at Gangdong · Lindner Center of HOPE · Lumy Sawaki · Macquarie University, Australia · Mark L. Wolraich · Monarch Medical Research · NYU Langone Health · National Alliance for Research on Schizophrenia and Depression · National Center for Advancing Translational Sciences (NCATS) · National Center for Research Resources (NCRR) · National Institute on Aging (NIA) · National Institutes of Health (NIH) · Norwegian University of Science and Technology · Orion Corporation, Orion Pharma · Ortho-McNeil Janssen Scientific Affairs, LLC · Patient-Centered Outcomes Research Institute · Peking University · Pfizer · Poitiers University Hospital · RWTH Aachen University · Radboud University Medical Center · STM Pharma PRO srl · Satish R. Raj · Seoul National University Childrens Hospital · Seoul National University Hospital · Sharon Walsh · State University of New York at Buffalo · Tanta University · Temple University · The University of Texas Health Science Center, Houston · US Department of Veterans Affairs · University of California, Irvine · University of California, Los Angeles · University of California, San Diego · University of Cincinnati · University of Colorado, Boulder · University of Florence · University of Iowa · University of Kentucky · University of Nebraska · University of Oklahoma · University of Pennsylvania · University of Texas Southwestern Medical Center · University of Turku · University of Waterloo · VIS Ethic Research Srl · all 82 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed attention deficit-hyperactivity disorder 1 milestone
Filed	US (FDA)	—	attention deficit-hyperactivity disorder	2002-01-24	“Lilly filed a new drug application (NDA) with the FDA for the use of atomoxetine” lilly.com ↗
Approved Indication not stated 2 milestones
Label expansions (4)	US (FDA)	STRATTERA	—	2005-05-26 – 2008-07-23	fda.gov ↗
Approved	US (FDA)	STRATTERA	—	2002-11-26	fda.gov ↗

Trials 132 · started per year

today

US approved 2002

19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT06841666	Feb → Aug 2025 overdue	attention deficit-hyperactivity disorder, nocturnal enuresis	Tanta University	Not yet recruiting	No outcome recorded
Phase 0	NCT00780650	May 2009 → Aug 2018	type 1 diabetes mellitus	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 18 trials
Phase 1	NCT05708274	Jan 2023 → Oct 2025	spinal cord injury	Bronx VA Medical Center	Completed	No outcome recorded
Phase 1	NCT03808740	Jul 2018 → May 2021	orthostatic hypotension	Vanderbilt University Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01435213	Sep 2011 → Jan 2012	—	University of Turku	Completed	No outcome recorded
Phase 1	NCT02014064	Aug 2009 → Aug 2012	methamphetamine dependence	University of California, Los Angeles	Completed	No outcome recorded
Phase 1	NCT00697138	Jun 2006 → Jan 2012	cocaine dependence	University of Kentucky	Completed	No outcome recorded
Phase 1	NCT00265265	Aug 2005 → Sep 2006	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 1	NCT01408589	Jun 2005 → Dec 2007	alcohol dependence	University of Colorado, Boulder	Terminated	No outcome recorded
Phase 1	NCT00223691	Mar 2002 → Jan 2017	autonomic nervous system disorder, orthostatic hypotension	Vanderbilt University	Completed	Mixed
Phase 1/28 trials · 1 met primary · 1 missed
Phase 1/2	NCT07577661	Sep 2026 → Sep 2028 expected	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT05550246	May 2022 → Dec 2024	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Unknown	No outcome recorded
Phase 1/2	NCT02046551	Apr 2014 → Feb 2017	nicotine dependence	Yale University	Withdrawn	No outcome recorded Stop: Business
Phase 1/2	NCT00573859	Sep 2006 → Jun 2010	attention deficit-hyperactivity disorder	University of California, Irvine	Completed	Met primary
Phase 1/2	NCT00607568	Jun 2006 → Aug 2007	—	Yale University	Completed	No outcome recorded
Phase 1/2	NCT00611936	Jun 2006 → Aug 2007	—	Yale University	Completed	No outcome recorded
Phase 1/2	NCT00262470	Apr 1997 → Dec 2029 expected	cardiac rhythm disease	Satish R. Raj	Active not recruiting	Missed primary
Phase 1/2	NCT00089869	—	schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 224 trials · 2 met primary · 1 missed
Phase 2	NCT05933603	Sep 2023 → Jun 2026 overdue	Down syndrome, obstructive sleep apnea syndrome	University of Arizona	Active not recruiting	No outcome recorded
Phase 2	NCT05448443	Jun 2022 → May 2024	obesity-hypoventilation syndrome	Istituto Auxologico Italiano	Completed	Met primary
Phase 2	NCT04354103	May 2022 → Jan 2024	Tourette syndrome	Poitiers University Hospital	Terminated	No outcome recorded
Phase 2	NCT04905979	Jul 2021 → Jan 2023	hypertensive disorder, obstructive sleep apnea syndrome	Apnimed	Completed	No outcome recorded
Phase 2	NCT04565288	May 2021 → May 2023	alcohol dependence	Brown University	Completed	No outcome recorded
Phase 2	NCT04631107	Dec 2020 → May 2021	obstructive sleep apnea syndrome	Apnimed	Completed	Met primary
Phase 2	NCT03919955	Sep 2019 → Sep 2023	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 2	NCT03845023	Mar → Oct 2019	obstructive sleep apnea syndrome	Apnimed	Completed	No outcome recorded
Phase 2	NCT03091400	Mar 2017 → Jun 2018	cognitive disorder, multiple sclerosis	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 2	NCT01863251	May 2013 → Aug 2014	opiate dependence	Yale University	Completed	No outcome recorded
Phase 2	NCT01522404	Mar 2012 → Oct 2017	cognitive impairment with or without cerebellar ataxia	Emory University	Completed	No outcome recorded
Phase 2	NCT00636818	Mar → Sep 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00530335	Sep 2007 → Apr 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00617201	Jul 2007 → Aug 2011	substance abuse	Sharon Walsh	Completed	No outcome recorded
Phase 2	NCT02788357	Nov 2006 → Dec 2012	—	Lumy Sawaki	Completed	No outcome recorded
Phase 2	NCT00029614	May 2006 → Jul 2007	attention deficit-hyperactivity disorder, substance-related disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 2	NCT00360269	Nov 2005 → Jun 2008	attention deficit-hyperactivity disorder, cannabis dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT00368849	Nov 2005 → Feb 2008	Huntington disease	University of Iowa	Completed	Missed primary
Phase 2	NCT00142961	Oct 2005 → Jan 2007	attention deficit-hyperactivity disorder, cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00420498	Aug 2005 → Sep 2007	schizophrenia	Yale University	Completed	No outcome recorded
Phase 2	NCT00167297	Nov 2004 → Jul 2005	cannabis dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00174226	Nov 2004 → Jan 2006	attention deficit-hyperactivity disorder	Pfizer	Completed	No outcome recorded
Phase 2	NCT00218543	Jun 2004 → Mar 2007	attention deficit-hyperactivity disorder, substance-related disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00485628	Apr → Oct 2003	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded

Phase 2/33 trials · 1 missed
Phase 2/3	NCT00260533	Nov 2005 → Jul 2008	social phobia	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00191295	Feb 2005 → Sep 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2/3	NCT00191009	Oct 2003 → Jan 2006	Alzheimer disease	Eli Lilly and Company	Completed	No outcome recorded
Phase 329 trials · 6 met primary · 1 missed
Phase 3	NCT07316296	Jan 2026 → Jul 2027 expected	Parkinson disease	Radboud University Medical Center	Recruiting	No outcome recorded
Phase 3	NCT06566820	Jul 2024 → Jun 2026 overdue	obstructive sleep apnea syndrome	Apnimed	Enrolling by invitation	No outcome recorded
Phase 3	NCT05813275	Sep 2023 → Mar 2025	obstructive sleep apnea syndrome	Apnimed	Completed	Met primary
Phase 3	NCT03651856	Jan 2013 → Feb 2014	Parkinson disease, primary progressive freezing gait	Medical University of South Carolina	Completed	No outcome recorded
Phase 3	NCT01244490	Jan 2011 → May 2013	attention deficit-hyperactivity disorder	Shire	Completed	Met primary
Phase 3	NCT00969618	Nov 2009 → Jan 2012	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00962104	Aug 2009 → Feb 2011	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00700427	Jun 2008 → Aug 2011	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00498173	Jul 2007 → Oct 2015	autism	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00447278	Mar 2007 → Mar 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00320528	Apr 2006 → Oct 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00255138	Nov 2005 → ?	cancer, cognitive disorder	Temple University	Withdrawn	No outcome recorded
Phase 3	NCT00418262	Aug 2005 → Apr 2015	attention deficit-hyperactivity disorder, fetal alcohol syndrome	University of Oklahoma	Completed	No outcome recorded
Phase 3	NCT00191945	May 2005 → Feb 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00191386	May 2005 → Aug 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191542	Mar 2005 → Aug 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00192023	Oct 2004 → Aug 2006	attention deficit-hyperactivity disorder, oppositional defiant disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00191737	Oct 2004 → Feb 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191516	Oct 2004 → Feb 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00386581	Jul 2004 → Feb 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191659	Jun 2004 → Apr 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191880	May 2004 → Jun 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00557960	Feb → Oct 2004	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 3	NCT00485459	Feb → Nov 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00485550	Jan 2004 → Mar 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191698	Dec 2003 → Jun 2005	attention deficit-hyperactivity disorder, oppositional defiant disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00486083	Dec 2003 → Oct 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00485407	Jul 2003 → Jun 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00190684	Aug 2000 → Oct 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded

Phase 450 trials · 9 met primary · 1 missed
Phase 4	NCT06573970	Apr 2026 → Jun 2029 expected	post-traumatic stress disorder	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT07280468	Mar 2026 → Jan 2030 expected	Down syndrome, obstructive sleep apnea syndrome	University of Arizona	Recruiting	No outcome recorded
Phase 4	NCT06295562	Nov 2024 → Oct 2025	obstructive sleep apnea syndrome	China Medical University Hospital	Completed	No outcome recorded
Phase 4	NCT03350659	Jan 2018 → Jan 2019	orthostatic hypotension	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT03661788	May 2016 → Dec 2017	attention deficit-hyperactivity disorder	RWTH Aachen University	Completed	No outcome recorded
Phase 4	NCT03250013	Apr 2014 → Jan 2022	attention deficit-hyperactivity disorder	Göteborg University	Completed	No outcome recorded
Phase 4	NCT01678209	Oct 2012 → Apr 2018	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT02623114	May 2012 → Aug 2016	attention deficit-hyperactivity disorder	Seoul National University Childrens Hospital	Unknown	No outcome recorded
Phase 4	NCT01339286	Mar → Dec 2011	attention deficit-hyperactivity disorder	Peking University	Unknown	No outcome recorded
Phase 4	NCT01133847	Nov 2010 → Jun 2015	attention deficit-hyperactivity disorder, reading disorder	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT01127646	Jun 2010 → May 2011	attention deficit-hyperactivity disorder	Eli Lilly and Company	Terminated	No outcome recorded
Phase 4	NCT00856063	Mar → Dec 2009	attention deficit-hyperactivity disorder	University of Arizona	Completed	No outcome recorded
Phase 4	NCT00716274	Sep 2008 → Jul 2016	attention deficit-hyperactivity disorder, dyslexia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00687609	Sep 2008 → Jun 2009	attention deficit-hyperactivity disorder, substance abuse	Eli Lilly and Company	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00760747	Sep 2008 → Aug 2010	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Missed primary
Phase 4	NCT00607919	Mar 2008 → Nov 2010	attention deficit-hyperactivity disorder, dyslexia	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00546910	Oct 2007 → May 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00510276	Aug 2007 → Feb 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00471354	Apr 2007 → Nov 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00918567	Jan 2007 → May 2008	attention deficit-hyperactivity disorder	State University of New York at Buffalo	Completed	No outcome recorded
Phase 4	NCT00406354	Nov 2006 → Jan 2009	attention deficit-hyperactivity disorder, oppositional defiant disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00380692	Oct 2006 → May 2008	attention deficit-hyperactivity disorder, autism	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00299234	Jun 2006 → Dec 2007	attention deficit-hyperactivity disorder	Monarch Medical Research	Terminated	No outcome recorded
Phase 4	NCT00327834	May 2006 → Mar 2007	binge eating disorder	Lindner Center of HOPE	Completed	Met primary
Phase 4	NCT00252278	Nov 2005 → ?	attention deficit-hyperactivity disorder, insomnia	Rhode Island Hospital	Unknown	No outcome recorded
Phase 4	NCT00254462	Oct 2005 → Aug 2008	attention deficit-hyperactivity disorder	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT00216918	Sep 2005 → Jun 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00190879	Jun 2005 → May 2007	attention deficit-hyperactivity disorder, social phobia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00566371	Jun 2005 → Dec 2008	attention deficit-hyperactivity disorder, insomnia	Rhode Island Hospital	Completed	No outcome recorded
Phase 4	NCT00191906	Apr 2005 → Dec 2007	attention deficit-hyperactivity disorder, reading disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00191633	Apr 2005 → Jun 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00218322	Sep 2004 → Mar 2006	attention deficit-hyperactivity disorder, substance-related disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00181948	Sep 2004 → Sep 2007	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00190736	Sep 2004 → Sep 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00190775	Sep 2004 → Jul 2009	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00190957	Aug 2004 → Jan 2006	alcohol abuse, attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00485875	Jun 2004 → Jan 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00517647	Apr 2004 → Mar 2008	attention deficit-hyperactivity disorder	University of Arizona	Completed	No outcome recorded
Phase 4	NCT00191035	Mar 2004 → Nov 2006	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00485849	Feb → Oct 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00585910	Jan 2004 → Dec 2007	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00181740	Dec 2003 → Jul 2005	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00181766	Dec 2003 → Jul 2008	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00222794	Nov 2003 → Jul 2006	schizoaffective disorder, schizophrenia	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00190931	Nov 2003 → Jul 2005	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00191048	Oct 2003 → Mar 2006	attention deficit-hyperactivity disorder, dyslexia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00486122	Sep 2003 → Jun 2004	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00628394	Sep 2003 → Feb 2011	schizophrenia	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00485862	Jun 2003 → Jan 2005	depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00866996	? → Dec 2003	attention deficit-hyperactivity disorder	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded

Phase not applicable8 trials · 3 missed
—	NCT07239791	Nov 2025 → Nov 2027 expected	—	Centre Hospitalier St Anne	Recruiting	No outcome recorded
—	NCT05278104	Sep 2023 → Oct 2024	attention deficit-hyperactivity disorder	Boehringer Ingelheim	Completed	Missed primary
—	NCT00702364	Jan 2008 → Mar 2012	traumatic brain injury	Craig Hospital	Completed	No outcome recorded
—	NCT00356070	Jan → Dec 2006	attention deficit-hyperactivity disorder	Norwegian University of Science and Technology	Completed	No outcome recorded
—	NCT00399763	Sep 2005 → Feb 2008	attention deficit-hyperactivity disorder, substance abuse	Denver Health and Hospital Authority	Completed	Missed primary
—	NCT00953862	Jul 2005 → Apr 2008	attention deficit-hyperactivity disorder	NYU Langone Health	Completed	No outcome recorded
—	NCT00286949	Jan 2005 → Jun 2008	Parkinson disease	Johns Hopkins University	Completed	No outcome recorded
—	NCT00161031	Apr 2004 → Dec 2006	schizophrenia	University of Maryland, Baltimore	Completed	Missed primary
Comparator or background therapy59 trials
Phase 0	NCT02879136 Comparator	Jan 2017 → Dec 2025	Parkinson disease	Hubert Fernandez	Completed	No outcome recorded
Phase 1	NCT01794975 Comparator	Aug → Dec 2012	—	University of Turku	Completed	No outcome recorded
Phase 1	NCT01019707 Comparator	Oct 2009 → Dec 2010	methamphetamine dependence, substance abuse	University of California, Los Angeles	Terminated	No outcome recorded Stop: Business
Phase 1	NCT01343628 Comparator	Jan 2008 → Feb 2012	alcohol sensitivity, acute, alcohol-induced mental disorder	University of Virginia	Terminated	No outcome recorded Stop: Business
Phase 1	NCT00417794 Comparator	Aug 2005 → Apr 2015	attention deficit-hyperactivity disorder, fetal alcohol syndrome	University of Oklahoma	Completed	No outcome recorded
Phase 1/2	NCT05944965 Comparator	Dec 2023 → Jun 2025	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 1/2	NCT05293600 Comparator	Jul 2023 → Oct 2026 expected	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT05350215 Comparator	Jun 2022 → Dec 2026 expected	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT05101122 Comparator	Oct 2021 → Apr 2022	obstructive sleep apnea syndrome	Apnimed	Completed	No outcome recorded
Phase 1/2	NCT03720353 Comparator	Dec 2018 → Dec 2019	—	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 1/2	NCT02908529 Comparator	Sep 2016 → Dec 2017	obstructive sleep apnea syndrome	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 1/2	NCT01557569 Comparator	Apr 2012 → Jun 2015	methamphetamine dependence	University of Arkansas	Completed	No outcome recorded
Phase 2	NCT06899178 Comparator	Apr 2025 → Jul 2028 expected	obesity due to melanocortin 4 receptor deficiency	Icahn School of Medicine at Mount Sinai	Not yet recruiting	No outcome recorded
Phase 2	NCT06542887 Background	Oct 2024 → Oct 2025 overdue	attention deficit-hyperactivity disorder	Ain Shams University	Not yet recruiting	No outcome recorded
Phase 2	NCT05071612 Comparator	Nov 2021 → Jul 2022	obstructive sleep apnea syndrome	Apnimed	Completed	Met primary
Phase 2	NCT04580394 Comparator	Oct 2020 → May 2021	obstructive sleep apnea syndrome	Apnimed	Completed	No outcome recorded
Phase 2	NCT04115878 Comparator	Oct 2020 → Dec 2022	Down syndrome, obstructive sleep apnea syndrome	University of Arizona	Completed	No outcome recorded
Phase 2	NCT04445688 Comparator	Jul → Dec 2020	obstructive sleep apnea syndrome	Apnimed	Completed	Met primary
Phase 2	NCT03324581 Comparator	Nov 2017 → Oct 2018	attention deficit-hyperactivity disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	Met primary
Phase 2	NCT02784535 Comparator	Aug 2016 → May 2021	orthostatic hypotension	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 2	NCT02500732 Comparator	Jul 2015 → Jan 2018	syncope, familial vasovagal	University of Calgary	Completed	No outcome recorded
Phase 2	NCT01738191 Comparator	Nov 2012 → Aug 2014	Parkinson disease, cognitive disorder	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT01399827 Comparator	Feb 2012 → Nov 2017	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00880217 Comparator	May 2009 → Jan 2010	attention deficit-hyperactivity disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	Missed primary
Phase 2	NCT00562055 Comparator	Nov 2007 → ?	attention deficit-hyperactivity disorder	Pfizer	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT00548327 Comparator	Oct 2007 → Nov 2011	amnestic disorder, schizophrenia	National Institute of Mental Health (NIMH)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00528697 Comparator	Sep 2007 → Apr 2008	attention deficit-hyperactivity disorder	AbbVie	Completed	Missed primary
Phase 2	NCT00429091 Comparator	Jan → Aug 2007	attention deficit-hyperactivity disorder	Abbott	Completed	No outcome recorded
Phase 3	NCT05159687 Comparator	Jun 2022 → Sep 2026 overdue	—	University of Calgary	Recruiting	No outcome recorded
Phase 3	NCT04216186 Comparator	Nov 2018 → Dec 2030 expected	attention deficit-hyperactivity disorder	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT01106430 Comparator	Jun 2010 → Jul 2012	attention deficit-hyperactivity disorder	Shire	Completed	Met primary
Phase 3	NCT01330693 Comparator	Sep 2009 → Nov 2015	attention deficit-hyperactivity disorder	University of Cincinnati	Unknown	No outcome recorded
Phase 3	NCT00568685 Comparator	Nov 2007 → Nov 2008	attention deficit-hyperactivity disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00216281 Comparator	Sep 2005 → Oct 2006	schizophrenia	Indiana University	Terminated	No outcome recorded
Phase 4	NCT07679282 Comparator	Sep 2026 → Mar 2030 expected	obstructive sleep apnea syndrome	Sairam Parthasarathy	Recruiting	No outcome recorded
Phase 4	NCT04085172 Comparator	Sep 2019 → Sep 2025	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 4	NCT03781765 Comparator	Jun 2019 → Sep 2025 overdue	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 4	NCT02287038 Comparator	Oct 2014 → Mar 2017	attention deficit-hyperactivity disorder, post-traumatic stress disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT02352051 Comparator	Feb → Oct 2014	attention deficit-hyperactivity disorder	TC Erciyes University	Completed	No outcome recorded
Phase 4	NCT01340885 Comparator	Jan 2011 → Jan 2013	Parkinson disease	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT00844753 Comparator	Oct 2008 → Apr 2014	attention deficit-hyperactivity disorder, autism	University of Rochester	Completed	No outcome recorded
Phase 4	NCT01065259 Comparator	Apr 2008 → Dec 2010	attention deficit-hyperactivity disorder	Peking University	Completed	No outcome recorded
Phase 4	NCT00938743 Comparator	Jan 2008 → Dec 2009	attention deficit-hyperactivity disorder	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 4	NCT00183391 Comparator	Jul 2005 → Jun 2011	attention deficit-hyperactivity disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT00488163 Comparator	Jan 2005 → Apr 2007	schizophrenia	Research Foundation for Mental Hygiene, Inc.	Completed	No outcome recorded
Phase 4	NCT00304161 Comparator	Jul 2004 → Dec 2008	Parkinson disease, depressive disorder	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT00506727 Comparator	Aug 2003 → Jul 2004	attention deficit-hyperactivity disorder	Shire	Completed	No outcome recorded
Phase 4	NCT01207622 Comparator	—	attention deficit-hyperactivity disorder, substance-related disorder	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT05351944 Comparator	May 2023 → Jan 2024	attention deficit-hyperactivity disorder, impulse control disorder	Alexandria University	Completed	No outcome recorded
—	NCT05635318 Comparator	Jan → Jun 2023	attention deficit-hyperactivity disorder	Assiut University	Unknown	No outcome recorded
—	NCT04782830 Comparator	Feb 2021 → Jun 2027 expected	orthostatic hypotension, pure autonomic failure	Vanderbilt University Medical Center	Recruiting	No outcome recorded
—	NCT03936491 Comparator	Aug 2019 → Jan 2021	attention deficit-hyperactivity disorder	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT02788851 Comparator	Apr 2016 → Dec 2018	attention deficit-hyperactivity disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
—	NCT02482649 Comparator	Jan 2013 → Aug 2015	attention deficit-hyperactivity disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT01802515 Comparator	Dec 2012 → Mar 2014	cocaine dependence, opiate dependence	Yale University	Terminated	No outcome recorded Stop: Enrollment
—	NCT02142140 Comparator	Dec 2012 → Feb 2019	attention deficit-hyperactivity disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
—	NCT02172183 Background	Apr 2012 → Mar 2014	attention deficit-hyperactivity disorder	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
—	NCT01498549 Comparator	Dec 2011 → Jul 2013	substance dependence	Yale University	Completed	No outcome recorded
—	NCT00611533 Comparator	May 2004 → Apr 2008	cognitive disorder, premature menopause	University of Pennsylvania	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 17

Date	Issuer	Release
2026-05-18	Apnimed	Results Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine apnimed.com ↗ The published Phase 3 data support AD109’s potential, if approved, to expand access to treatment for people with OSA who cannot tolerate or refuse PAP devices
2025-07-23	Apnimed	Results Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea apnimed.com ↗ today announced positive topline results from its second pivotal Phase 3 clinical trial of Apnimed’s lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg).
2025-07-17	Hyloris Developments	Results Hyloris Announces Positive Clinical Study Results for Atomoxetine Oral Solution hyloris.com ↗ The study demonstrated that Atomoxetine Oral Solution has comparable relative bioavailability 1 under fasted conditions to Strattera® capsules as sold in the U.S.
2025-05-19	Apnimed	Results Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea apnimed.com ↗ The SynAIRgy trial met its primary endpoint: mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo (p=0.001).
2018-08-15	Upsher-Smith Laboratories	Regulatory Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs upsher-smith.com ↗ Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six compounds with 13 strengths of generic drugs.
2010-08-31	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma announces USFDA approval for generic Strattera® Capsules sunpharma.com ↗ Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.
2008-05-08	Eli Lilly and Company	Regulatory FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents lilly.com ↗
2007-05-23	Eli Lilly and Company	Results Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse lilly.com ↗ Data from a recent clinical study showed Strattera(R) (atomoxetine HCl) improved symptoms of Attention- Deficit/Hyperactivity Disorder (ADHD) in patients with comorbid alcohol abuse disorder, suggesting ADHD can be treated safely and effectively with Strattera in patients with both disorders.
2006-10-27	Eli Lilly and Company	Results Study Suggests Strattera(R) was Effective in Treating ADHD in Children and Adolescents with ADHD and Reading Disorders lilly.com ↗ After taking Strattera for 16 weeks, both groups of patients aged 10 to 16 reported an improvement of nearly 50 percent in ADHD symptoms like inattentiveness, hyperactivity and impulsivity.
2006-05-24	Eli Lilly and Company	Results Study Suggests Atomoxetine Significantly Improved Functioning in Children with Both ADHD and Anxiety Disorders lilly.com ↗ At the end of the study, atomoxetine significantly reduced ADHD symptoms such as inattention, hyperactivity and impulsivity by 39 percent, compared to a four percent improvement in patients taking sugar pill.
2005-09-29	Eli Lilly and Company	Regulatory Lilly Announces Important Strattera(R) Label Update lilly.com ↗ INDIANAPOLIS, Sept 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Eli Lilly and Company (NYSE: LLY) today announced that it will update the product label globally for its attention-deficit/hyperactivity disorder (ADHD) medication, Strattera, to communicate new information regarding uncommon reports of suicidal thoughts among children and adolescents.
2005-05-24	Eli Lilly and Company	Results New Data Suggest Once-Daily Atomoxetine May Provide Symptom Relief for Up to 24 Hours lilly.com ↗ This study found morning or evening dosing produced similar core symptom reduction based on the ADHD-RS, a scale which assesses 18 individual symptoms related to ADHD (nine assess inattentive symptoms and the other nine assess hyperactive and impulsive symptoms).
2005-05-24	Eli Lilly and Company	Results New Analysis Highlights Gender Differences in ADHD Patients Treated with Atomoxetine lilly.com ↗ Females with Attention- Deficit/Hyperactivity Disorder (ADHD) and treated with atomoxetine HCl showed no difference in core ADHD symptom improvement compared to men yet women displayed greater emotional symptom improvement when treated.
2005-05-18	Eli Lilly and Company	Regulatory Non-stimulant Strattera More Widely Available for Attention- Deficit/Hyperactivity Disorder in Children and Adolescents in Europe lilly.com ↗ Strattera(R) (atomoxetine HCl), the only approved non-stimulant medication proven clinically effective at treating the symptoms of attention- deficit/hyperactivity disorder (ADHD), is now more widely available in Europe, following marketing authorizations granted by regulatory authorities in Germany, The Netherlands and Norway.
2004-12-17	Eli Lilly and Company	Regulatory Lilly Announces Important Liver Safety Update to Strattera(R) Label lilly.com ↗ Eli Lilly and Company announced today that it has added a bolded warning to the product label for Strattera, an attention deficit/hyperactivity disorder (ADHD) medication.
2004-06-25	Eli Lilly and Company	Results Strattera Controlled Symptoms of ADHD with Minimal Effect on Sleep lilly.com ↗ Parent and child diaries also showed that children on Strattera had less difficulty getting out of bed in the morning versus children taking methylphenidate.
2004-06-03	Eli Lilly and Company	Regulatory First Non-Stimulant ADHD Medication Available in the United Kingdom lilly.com ↗ Strattera® (atomoxetine HCl), a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD), is now approved for use in the United Kingdom and will be available by mid-July.

All press releases naming this drug 19 releases

Date	Issuer	Release
2026-05-18	Apnimed	Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine apnimed.com ↗
2025-07-23	Apnimed	Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea apnimed.com ↗
2025-07-17	Hyloris Developments	Hyloris Announces Positive Clinical Study Results for Atomoxetine Oral Solution hyloris.com ↗
2025-05-19	Apnimed	Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea apnimed.com ↗
2018-08-15	Upsher-Smith Laboratories	Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs upsher-smith.com ↗
2011-07-29	Eli Lilly and Company	U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent lilly.com ↗
2010-08-31	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces USFDA approval for generic Strattera® Capsules sunpharma.com ↗
2010-08-12	Eli Lilly and Company	U.S. District Court Rules Against Lilly Regarding Strattera Patent lilly.com ↗
2008-05-08	Eli Lilly and Company	FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents lilly.com ↗
2007-05-23	Eli Lilly and Company	Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse lilly.com ↗
2006-10-27	Eli Lilly and Company	Study Suggests Strattera(R) was Effective in Treating ADHD in Children and Adolescents with ADHD and Reading Disorders lilly.com ↗
2006-05-24	Eli Lilly and Company	Study Suggests Atomoxetine Significantly Improved Functioning in Children with Both ADHD and Anxiety Disorders lilly.com ↗
2005-09-29	Eli Lilly and Company	Lilly Announces Important Strattera(R) Label Update lilly.com ↗
2005-05-24	Eli Lilly and Company	New Data Suggest Once-Daily Atomoxetine May Provide Symptom Relief for Up to 24 Hours lilly.com ↗
2005-05-24	Eli Lilly and Company	New Analysis Highlights Gender Differences in ADHD Patients Treated with Atomoxetine lilly.com ↗
2005-05-18	Eli Lilly and Company	Non-stimulant Strattera More Widely Available for Attention- Deficit/Hyperactivity Disorder in Children and Adolescents in Europe lilly.com ↗
2004-12-17	Eli Lilly and Company	Lilly Announces Important Liver Safety Update to Strattera(R) Label lilly.com ↗
2004-06-25	Eli Lilly and Company	Strattera Controlled Symptoms of ADHD with Minimal Effect on Sleep lilly.com ↗
2004-06-03	Eli Lilly and Company	First Non-Stimulant ADHD Medication Available in the United Kingdom lilly.com ↗

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 202 sources stand behind the page.

Field	Value	Cited text
Known as	Atomoxetine	“adults with loud habitual snoring took atomoxetine plus oxybutynin for 10 days before bedtime at full adult doses (80 and 5 mg, respectively; half-dose run-in on days 1-3) and...” PMID 40471069 ↗ Sep 2025 184 “This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with...” PMID 24942409 ↗ Jun 2014 “CONCLUSIONS: This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin,...” PMID 35975547 ↗ Dec 2022 “RESEARCH QUESTION: Is 2 weeks of 500 mg acetazolamide plus 100 mg atomoxetine daily effective for OHS severity (reduction in mean nocturnal CO2 as the primary outcome)?” PMID 41015199 ↗ Sep 2025 “Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.” NCT02172183 ↗ “Recently, a non-stimulant pharmacological agent, atomoxetine (ATMX), has been reported to be effective and safe in school-age children with ADHD.” NCT00517647 ↗ “Medications (methylphenidate, amphetamine, atomoxetine) will be provided by the pharmacy according to routines in standard clinical treatment.” NCT03250013 ↗ “Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-26).” NCT05813275 ↗ “a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients.” NCT03651856 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ “single dose of Atomoxetine consisting of two 40 mg capsules (totaling 80 mg)” NCT05278104 ↗ Show 174 more sources
Known as	ATM	“Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit.” NCT03651856 ↗ 1 “Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor,” PMID 19910721 ↗ Dec 2009
Known as	ATMX	“The primary objective of the study is to investigate the efficacy of Atomoxetine (ATMX) in the treatments of adolescent and young adult Attention Deficit Hyperactivity Disorder...” NCT01207622 ↗ 2 “Recently, a non-stimulant pharmacological agent, atomoxetine (ATMX), has been reported to be effective and safe in school-age children with ADHD.” NCT00517647 ↗ “Atomoxetine (ATMX) blocks the NE transporter (NET), and increases extracellular levels of NE throughout the brain.” NCT00856063 ↗
Known as	ato	“Norepinephrine reuptake inhibitors such as atomoxetine (ato) can improve OSA by increasing pharyngeal muscle activity.” PMID 39305436 ↗ Sep 2024
Known as	Atomoxetine HCl	“Patients will take one oral capsules each day in the morning upon awakening, either JNJ-31001074 (1, 3, or 10 mg), matching atomoxetine HCL (40 or 80 mg), matching OROS...” NCT00880217 ↗ 1 “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗
Known as	atomoxetine hydrochloride	“To evaluate the effect of atomoxetine hydrochloride versus placebo on attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) in adolescents receiving...” PMID 20494267 ↗ Jun 2010 8 “Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or...” PMID 22519922 ↗ May 2012 “Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder” NCT00386581 ↗ “A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes” NCT00510276 ↗ “Drug: Atomoxetine hydrochloride” NCT00191386 ↗ “Drug: Atomoxetine Hydrochloride” NCT00191906 ↗ “Drug: Atomoxetine Hydrochloride” NCT00190775 ↗ NCT00568685 ↗ NCT04085172 ↗
Known as	Atomoxetine only	“Atomoxetine only” NCT03350659 ↗
Known as	ATX	“This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with...” PMID 24942409 ↗ Jun 2014 9 “The purpose of this study is to examine the efficacy of atomoxetine (ATX) treatment for the mild to moderate cognitive disturbances frequently experienced by women during the...” NCT00611533 ↗ “OBJECTIVE: To examine status of children with autism spectrum disorder (ASD) 10 months after a 34-week clinical trial of atomoxetine (ATX) and parent training (PT).” PMID 29694241 ↗ Apr 2018 “Atomoxetine (ATX) once daily was compared with placebo (PBO) in adults with attention-deficit/hyperactivity disorder (ADHD) at 12 and 24 weeks.” PMID 21406998 ↗ Mar 2011 “In this 7 week placebo-controlled study, Atomoxetine (ATX) at mean dose of 1.3 mg/kg, significantly reduced teacher rated ADHD symptoms” NCT00918567 ↗ “the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX)” PMID 23959815 ↗ Dec 2013 “An atomoxetine (ATX) arm was included to provide reference data against placebo.” PMID 25453486 ↗ Oct 2014 “using atomoxetine (ATX) as an add-on medication to other therapies” NCT02287038 ↗ “A single dose of Atomoxetine (ATX) (40 mg) will be administered.” NCT05708274 ↗ “atomoxetine (ATX)” PMID 26779845 ↗ Jan 2016
Known as	LY139603	“Atomoxetine (LY139603)” NCT00636818 ↗
Known as	Straterra	“atomoxetine (brand name: Straterra)” NCT04565288 ↗
Known as	Strattera	“The study will evaluate the effectiveness of atomoxetine (Strattera) with and without Parent Management Training (PMT) in children with Autism, Asperger's Disorder, or...” NCT00844753 ↗ 21 “The purpose of this study is to determine if atomoxetine (a common brand name is Strattera), a medicine that is used for treating older children with Attention Deficit and...” NCT00517647 ↗ “The Formal Observation of Concerta versUs Strattera (FOCUS) study was conducted to assess, in children with ADHD, treatment outcomes with Concerta [OROS methylphenidate (MPH)],...” PMID 16350601 ↗ Oct 2005 “Strattera (atomoxetine) is a non-stimulant specific norepinephrine reuptake inhibitor recently approved by the Food and Drug Administration for the treatment of child,...” NCT00181766 ↗ “Strattera (atomoxetine) is a non-stimulant presynaptic norepinephrine reuptake inhibitor recently approved by the Food and Drug Administration for use in child, adolescent and...” NCT00181948 ↗ “Atomoxetine (Strattera®) is a non-stimulant drug used to treat ADHD symptoms in both children and adults, and there is evidence that it may also have a positive effect on sleep...” NCT00252278 ↗ “Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school...” NCT00918567 ↗ “The purpose of this study is to assess potential interactions between intravenous (i.v.) cocaine and atomoxetine (Strattera) administered orally in four escalating doses.” NCT00265265 ↗ “The second specific aim is to determine the efficacy of atomoxetine (Strattera®) as a putative agonist replacement pharmacotherapy for cocaine dependence.” NCT00697138 ↗ “Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.” NCT00167297 ↗ “Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)” NCT05635318 ↗ Show 11 more sources
Action	Inhibit	“Atomoxetine is a nonstimulant, selective norepinephrine reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder.” PMID 19358788 ↗ Apr 2009
Modality	Other / unclassified	“the non-stimulant noradrenergic compound atomoxetine (ATX)” PMID 23959815 ↗ Dec 2013
Route	Oral	“subjects will take one 25mg capsule of Atomoxetine orally” NCT00167297 ↗